This topic contains a solution. Click here to go to the answer

Author Question: If you were to design an intensive action-oriented treatment to support durable change in clients ... (Read 76 times)

Coya19@aol.com

  • Hero Member
  • *****
  • Posts: 601
If you were to design an intensive action-oriented treatment to support durable change in clients with a particular problem, you would expect that:
 
  a. it would be a very good match for those in the precontemplation and contemplation stages of change, but be detrimental for those already in the action stage of change.
  b. it would help those in the contemplation stage by moving them forward to preparation and action, but be of little impact on precontemplators or those already in the action stage of change.
  c. it would be a poor match for precontemplators and most contemplators, but quite successful for those ready for action.
  d. it would help those in the contemplation or preparation stages, but be a poor match for those in the precontemplation or action stage of change.

Question 2

The most likely stage of change profile for therapy continuers is:
 
  a. precontemplation. c. preparation.
  b. contemplation. d. action.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Chelseyj.hasty

  • Sr. Member
  • ****
  • Posts: 319
Answer to Question 1

C

Answer to Question 2

B




Coya19@aol.com

  • Member
  • Posts: 601
Reply 2 on: Jul 30, 2018
:D TYSM


mohan

  • Member
  • Posts: 362
Reply 3 on: Yesterday
Wow, this really help

 

Did you know?

Excessive alcohol use costs the country approximately $235 billion every year.

Did you know?

Signs and symptoms of a drug overdose include losing consciousness, fever or sweating, breathing problems, abnormal pulse, and changes in skin color.

Did you know?

Human kidneys will clean about 1 million gallons of blood in an average lifetime.

Did you know?

Elderly adults are at greatest risk of stroke and myocardial infarction and have the most to gain from prophylaxis. Patients ages 60 to 80 years with blood pressures above 160/90 mm Hg should benefit from antihypertensive treatment.

Did you know?

The first monoclonal antibodies were made exclusively from mouse cells. Some are now fully human, which means they are likely to be safer and may be more effective than older monoclonal antibodies.

For a complete list of videos, visit our video library